LON:TRX Tissue Regenix Group (TRX) Share Price, News & Analysis GBX 32.80 +1.80 (+5.81%) As of 12:26 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsBuy This Stock About Tissue Regenix Group Stock (LON:TRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tissue Regenix Group alerts:Sign Up Key Stats Today's Range 30▼ 32.8050-Day Range 31▼ 4652-Week Range 30▼ 75Volume214,611 shsAverage Volume47,258 shsMarket Capitalization£29.57 millionP/E RatioN/ADividend Yield4.12%Price TargetN/AConsensus RatingN/A Company OverviewTissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care. In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.Read More… Receive TRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TRX Stock News HeadlinesTissue Regenix Scraps Sale Plans, Flags Profit AheadApril 8, 2025 | marketwatch.comTissue Regenix Group Regulatory NewsFebruary 18, 2025 | lse.co.ukHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 2, 2025 | Brownstone Research (Ad)Tissue Regenix Group Share Chat (TRX)November 3, 2024 | lse.co.ukTissue Regenix Group plc (TRX.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comAnalysts Expect Breakeven For Tissue Regenix Group plc (LON:TRX) Before LongSeptember 13, 2024 | finance.yahoo.comTissue Regenix Group PLC (LSW.BE)August 5, 2024 | nz.finance.yahoo.comTissue Regenix Group plc (TRX.L)July 19, 2024 | nz.finance.yahoo.comSee More Headlines TRX Stock Analysis - Frequently Asked Questions How have TRX shares performed this year? Tissue Regenix Group's stock was trading at GBX 60 at the beginning of 2025. Since then, TRX shares have decreased by 45.3% and is now trading at GBX 32.80. View the best growth stocks for 2025 here. How were Tissue Regenix Group's earnings last quarter? Tissue Regenix Group plc (LON:TRX) posted its earnings results on Wednesday, September, 2nd. The company reported ($0.16) earnings per share for the quarter. Tissue Regenix Group had a negative net margin of 3.46% and a negative trailing twelve-month return on equity of 2.87%. How do I buy shares of Tissue Regenix Group? Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Tissue Regenix Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank AB (publ) (SWDBY), Trevena (TRVN) and Barrick Gold (ABX). Company Calendar Last Earnings9/02/2020Today5/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPrecious Metals Current SymbolLON:TRX CIKN/A Webwww.tissueregenix.com Phone+44-1904-567609FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.97) Trailing P/E RatioN/A Forward P/E Ratio65.31 P/E GrowthN/ANet Income£-1,105,225.70 Net Margins-3.46% Pretax MarginN/A Return on Equity-2.87% Return on Assets0.50% Debt Debt-to-Equity Ratio31.16 Current Ratio4.03 Quick Ratio2.36 Sales & Book Value Annual Sales£31.98 million Price / Sales0.92 Cash FlowGBX 5.75 per share Price / Cash Flow5.70 Book ValueGBX 41.58 per share Price / Book0.79Miscellaneous Outstanding Shares90,155,317Free FloatN/AMarket Cap£29.57 million OptionableNot Optionable Beta1.61 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:TRX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tissue Regenix Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tissue Regenix Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.